trial

Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone

NCTId NCT01119638
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 40 (actual)
Sponsored by Abarbanel Mental Health Center
Primary completion 2010-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
40 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2008-04
Primary completion
2010-04
Eligibility
ALL · 55 Years · 95 Years

Interventions & indications

Drugs
escitalopramRisperidone

Sponsors

Abarbanel Mental Health CenterLead Sponsor

Investigators

1
Yoram Barak, MD, MHAPrincipal Investigator

Sites

1 total
Bat Yam, Israel

Facts & assertions

4 sourced
Enrollment
40
Phase
PHASE4
Primary Completion Date
2010-04
Status
COMPLETED
relationships
The graph out of here
drug
escitalopram
drug
Risperidone
drug
lead_sponsor
Abarbanel Mental Health Center
company
indication
Psychomotor Agitation
indication
Dementia
indication
Psychosis
indication
investigator
Yoram Barak, MD, MHA
person